STXS

Stereotaxis, Inc. 10-Q Summary: Period Ended June 30, 2010

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Stereotaxis, Inc., a developer of advanced cardiology instrument control systems (NIOBE and ODYSSEY) for interventional surgical suites. The report covers the three and six-month periods ended June 30, 2010. The company is classified as an accelerated filer and is not a shell company. As of August 2, 2010, there were 50,372,024 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 19% year-over-year for the quarter ($15.0M vs. $12.6M) and 8% for the six-month period ($25.6M vs. $23.8M). System revenue grew 16% in the quarter, driven by increased sales of ODYSSEY systems. Disposables and service revenue grew 24% in the quarter due to an expanded installed base.
• Margin Improvement: Gross margin improved to 67% for the quarter (from 63% in 2009) and 69% for the six-month period (from 66% in 2009). This was driven by a shift toward recurring revenue and lower maintenance costs compared to the prior year.
• Accounting Change Impact: A change in revenue recognition policy for ODYSSEY Vision systems (recognizing revenue upon delivery rather than installation) added $1.2 million in revenue and $0.6 million in gross margin for the quarter ended June 30, 2010.
• Debt Restructuring: Short-term debt increased significantly to $19.5 million (from $3.3 million at year-end 2009) due to the reclassification of $10 million of debt from long-term to current. Total debt carrying amount was $26.65 million.
• Other Income: Other income increased to $2.51 million for the quarter (from $0.30 million in 2009) primarily due to a favorable mark-to-market adjustment on warrant liabilities.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects negative cash flow from operations in 2010. The company had a working capital deficit of approximately $0.2 million at June 30, 2010, compared to a surplus of $22.9 million at December 31, 2009. This shift was due to debt reclassification and cash usage from operations.
• Capital Resources: The company has $22.0 million in cash and a revolving credit facility with $4.3 million of additional borrowing capacity available as of June 30, 2010. Management believes existing resources are sufficient to fund operations for the next 12 months, assuming renewal of credit facilities maturing in March 2011.
• Biosense Webster Agreement: The company has a significant debt obligation ($11.2 million remaining) to Biosense Webster related to royalty advances and deferred R&D expenses. This debt is repayable by December 31, 2011, or upon an "Accelerating Recoupment Event" (e.g., raising $50 million in equity).
• Risks: Key risks include the need for additional financing if cash burn continues, foreign exchange exposure (approx. 20% of revenue in foreign currencies), and reliance on third-party installers for revenue recognition timing.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the "tangible net worth" covenant required by the revolving credit facility.
• Revenue Recognition Policy: Confirm the sustainability of the revenue boost from the ODYSSEY Vision installation policy change.
• Biosense Webster Recoupment: Monitor the quarterly "Supplemental Payments" required to Biosense Webster and the risk of an Accelerating Recoupment Event triggering early repayment.
• Warrant Liability Volatility: Note that "Other Income" is heavily influenced by the fair value adjustment of warrant liabilities, which fluctuates with the company's stock price.
• Cash Burn Rate: Assess the runway provided by the $22 million cash balance against the $13.1 million cash used in operating activities over the last six months.